Looking for a buyer, GSK totes positive Tanzeum data at EASD

London-listed GlaxoSmithKline (LSE: GSK) has presented positive data from the Harmony Outcomes study at the European Association for the Study of Diabetes.

GSK has been undertaking the study, in collaboration with the Duke Clinical Research Institute (DCRI), to assess the cardiovascular (CV) safety and efficacy of its GLP1 blocker Tanzeum (albiglutide), once marketed as Eperzan in Europe.

Despite the fact that GSK has since discontinued the product, it has committed to completing the trial, in order to “contribute important new evidence to the field.”